Institutional investors purchased a net $148.9 thousand shares of RGEN during the quarter ended March 2017 and now own 95.57% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
TIMESSQUARE CAPITAL MANAGEMENT L... Bought 512.3 Thousand shares of Repligen Corp
BLACKROCK FUND ADVISORS Bought 281.2 Thousand shares of Repligen Corp
MARSHALL WACE NORTH AMERICA LP Bought 257.3 Thousand shares of Repligen Corp